Grant: CIHR - ICR / Cancer Research Society Partnership - Res. Grants - Breast Cancer
Queen's University (Kingston, Ontario)
$65,000.00
Role of RIPK2 in Inflammatory Breast Cancer
FY 2023-24
Summary
Inflammatory Breast Cancer (IBC) is a rare type of breast cancer that is associated with an extremely poor prognosis. There are currently not any therapies designed to target this special type of breast cancer. We have found that this cancer may be driven by a protein (RIPK2) that is normally used by the immune system. This grant will explore how RIPK2 may promote IBC progression and will determine whether a drug currently being tested for the treatment of inflammatory bowel diseases may be repurposed to treat IBCs. This would reveal a desperately needed therapy for a cancer for which there are few effective therapeutic options.
Department
Program
CIHR - ICR / Cancer Research Society Partnership - Res. Grants - Breast Cancer
Location
Ontario, Canada
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
516991
Name
Postovit Lynne-Marie
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
Cancer Research Society Inc.; Cancer Research Society Inc.
Instname2
Cancer Research
Prcname2
Special Cases
Projecttitle
Role of RIPK2 in Inflammatory Breast Cancer
Programtype2
Operating Grants
Orgnameinp2
Queen's University (Kingston, Ontario)
Cihramount2
$65,000
Cihrequipment2
$0
Programname2
CIHR - ICR / Cancer Research Society Partnership - Res. Grants - Breast Cancer
Keyworddelim
Breast Cancer
Abstract
Inflammatory Breast Cancer (IBC) is a rare type of breast cancer that is associated with an extremely poor prognosis. There are currently not any therapies designed to target this special type of breast cancer. We have found that this cancer may be driven by a protein (RIPK2) that is normally used by the immune system. This grant will explore how RIPK2 may promote IBC progression and will determine whether a drug currently being tested for the treatment of inflammatory bowel diseases may be repurposed to treat IBCs. This would reveal a desperately needed therapy for a cancer for which there are few effective therapeutic options.
Competitiondate
202402
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Postovit, Lynne-Marie
Approvedterm
2 ans 0 mois
Cihrcontribution2
ICR~ $65,000~ $0~
